Navigation Links
Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
Date:12/9/2009

European Phase III clinical trials for Topical Interferon Alpha-2b (cervical dysplasia). As previously stated, these trials will require substantial funding beyond the Company's current resources.

The Company will continue to seek additional funding, primarily by way of equity offerings, to carry out its business plan and to minimize risks to its operations. The market, however, for equity financings for companies such as Helix is challenging, and the global economic downturn and credit crisis have added further challenges. There can be no assurance that additional funding by way of equity financing will be available. The failure of the Company to obtain additional funding on a timely basis may result in the Company reducing, delaying or cancelling one or more of its planned research, development and marketing programs and reducing related personnel, any of which could impair the current and future value of the business. Any additional equity financing, if secured, may result in significant dilution to the existing shareholders at the time of such financing. The Company may also seek additional funding from other sources, including technology licensing, co-development collaborations, and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products. There can be no assurance, however, that any alternative sources of funding will be available.

The Company's unaudited interim consolidated first quarter fiscal 2010 and 2009 financial statements are summarized below:




Consolidated Statements of Operations
for the three month period ended October 31
(thousand $, except for per share data)
---------------------------------------


                                       2009     2008
                                       ----     ----
Revenue:
  Product revenue                       903      921
  License fees & royalties              117      198
                      
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
4. Helix BioPharma Corp. Announces Fiscal 2009 Results
5. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)... special edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 ... highlighting the success of the prescription drug benefit, commonly referred to as Part D. ... and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
... Calif. , June 16 SanBio Inc. ( www.san-bio.com ) ... approved the clinical testing of their SB623 regenerative medicine product in patients ... marrow stromal cells (MSCs) isolated from healthy adult donors. , ... This Phase 1/2a clinical trial will test ...
... June 16 Trius Therapeutics, Inc. announced today ... and Drug Administration (FDA), under the Special Protocol Assessment (SPA) ... for the oral dosage form of torezolid phosphate for treatment ... double-blind pivotal study will compare the efficacy and safety of ...
Cached Medicine Technology:SanBio Receives FDA Clearance to Initiate Cell Therapy Clinical Studies for Stroke Recovery 2Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate 2
(Date:7/31/2015)... New York, New York (PRWEB) , ... ... ... Nationally renowned trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence ... from July 28th, 2015 was well received with a 94% approval rating ...
(Date:7/31/2015)... ... July 31, 2015 , ... As part of their company mission, ... support of animal welfare organizations is essential to the longevity of their business. ... the National Association of Professional Pet Sitters (NAPPS) annual Presents 4 Pets supply drive. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Transfinder, a software company ... Total sales were up 16 percent year-over-year for the first six months ended June ... said he expected Transfinder to beat last year’s record-revenue mark of $10.4 million. , ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... “HARMONY 2015”, one of the industry’s premier thought leadership symposiums, hosted by ... and 6. The event attracts over 250 “C”-level executives, administrators, directors of ...
(Date:7/31/2015)... ... 2015 , ... Mullin/Ashley Associates , a Mid-Atlantic branding, ... Awards national competition for a marketing communications campaign created for Atlantic General ... Coastal Maryland and Southern Delaware. , A Bronze Award was won for the ...
Breaking Medicine News(10 mins):Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2
... stem cell researchers and other medical professionals from throughout ... in the heart of California,s Central Coast horse region ... cell therapy and regenerative medicine to treat horses and ... Conference will be held at the Santa Ynez Valley ...
... ... has added a new limited partner to its first venture fund, bolstering the fund’s ... , ... 2010 -- Mission Bay Capital, LLC, has added a new limited partner to its ...
... ... Book Will Make You Money” to give the keynote speech at the Affiliate Summit 2010 ... (PRWEB) ... Affiliate Summit event to learn and network about how to create and promote a successful ...
... ... suggest some health plans have used rescission to invalidate insurance policies for pre-existing ... consumers seeking to appeal their insurer’s decision to rescind their healthcare insurance have ... ...
... , ... Xserve Virtualization Offerings Capabilities for Businesses and Cloud Services Providers. , ... Renton, WA (PRWEB) February 24, 2010 ... announced that it is extending its server virtualization offerings for Apple environments with the ...
... ... small business. , ... (PRWEB) February 24, 2010 -- Verndale, a leading mid-market web technology and consultancy firm ... business, which is redefining the way websites are designed and managed. With Jumpstart, clients ...
Cached Medicine News:Health News:Horse stem cell conference to draw veterinarians and human-health professionals 2Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 2Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 3Health News:QB3 Adds Zcube As Limited Partner In Mission Bay Capital Fund 4Health News:Online Business Marketing Consultant Jim Kukral Chosen To Keynote Affiliate Summit 2010 2Health News:Online Business Marketing Consultant Jim Kukral Chosen To Keynote Affiliate Summit 2010 3Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 2Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 3Health News:Health Plan Policy Rescission Won't Go Away, Says NAIRO 4Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 2Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 3Health News:Parallels Launches Parallels Server for Mac Bare Metal Edition 4Health News:Verndale Announces the Release of Jumpstart 2Health News:Verndale Announces the Release of Jumpstart 3
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma....
Mini Aprons are half aprons with an easy-on, easy-off Velcro-style closure that fastens securely in seconds. Color-coded sizes for easy identification. Offers 0.5 mm Pb equivalent protection....
... the first in portability and performance. CTU is ... a flexible, portable system with the state-of-the-art features of ... to an "E" size tank and has an optional ... it is needed.,The CTU Travel Case allows you to ...
Pilot and control your analysis at a touch. 26 parameters CBC/DIFF with autoloader...
Medicine Products: